Clinical Trials
Novo Nordisk's CagriSema Shows Superior Weight Loss in REDEFINE 2 Trial
Drugs.com
•
March 10, 2025
Novo Nordisk announced positive headline results from its REDEFINE 2 Phase 3 trial, demonstrating that CagriSema produced superior weight loss in adults with obesity or overweight and type 2 diabetes compared to semaglutide.
The positive results from Novo Nordisk's REDEFINE 2 trial are significant for the treatment of obesity and type 2 diabetes. CagriSema's superior weight loss compared to semaglutide, already a successful weight loss drug, suggests a potential new standard of care. This advancement could have profound implications for managing comorbidities associated with obesity and diabetes, such as cardiovascular disease and kidney disease. The findings underscore the ongoing research and development in innovative weight management therapies and their potential to improve patient outcomes.